395 related articles for article (PubMed ID: 9039343)
1. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
[TBL] [Abstract][Full Text] [Related]
2. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
3. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
[TBL] [Abstract][Full Text] [Related]
4. Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas.
de Herder WW; Reijs AE; de Swart J; Kaandorp Y; Lamberts SW; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med; 1999 Jan; 26(1):46-50. PubMed ID: 9933661
[TBL] [Abstract][Full Text] [Related]
5. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
6. Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
de Herder WW; Reijs AE; Feelders RA; van Aken MO; Krenning EP; Tanghe HL; van der Lely AJ; Kwekkeboom DJ
Eur J Endocrinol; 2006 Nov; 155(5):717-23. PubMed ID: 17062888
[TBL] [Abstract][Full Text] [Related]
7. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
8. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
Pirker W; Riedl M; Luger A; Czech T; Rössler K; Asenbaum S; Angelberger P; Kornhuber J; Deecke L; Podreka I; Brücke T
J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508
[TBL] [Abstract][Full Text] [Related]
9. Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors.
Pirker W; Brücke T; Riedl M; Clodi M; Luger A; Asenbaum S; Podreka I; Deecke L
J Neural Transm Gen Sect; 1994; 97(3):235-44. PubMed ID: 7873131
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic imaging of dopamine receptors in pituitary adenomas.
de Herder WW; Reijs AEM; Feelders RA; van Aken MO; Krenning EP; van der Lely AJ; Kwekkeboom DJ
Eur J Endocrinol; 2007 Apr; 156 Suppl 1():S53-S56. PubMed ID: 17413189
[TBL] [Abstract][Full Text] [Related]
11. Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma.
Verhoeff NP; Bemelman FJ; Wiersinga WM; van Royen EA
Eur J Nucl Med; 1993 Jun; 20(6):555-61. PubMed ID: 8339737
[TBL] [Abstract][Full Text] [Related]
12. Effects of quinagolide (CV 205-502), a selective D2-agonist, on vascular reactivity in patients with a prolactin-secreting adenoma.
Bodmer CW; Atkin SL; Savage MW; Masson EA; White MC
Clin Endocrinol (Oxf); 1995 Jul; 43(1):49-53. PubMed ID: 7641411
[TBL] [Abstract][Full Text] [Related]
13. In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas.
Scillitani A; Dicembrino F; Di Fazio P; Vettori PP; D'Angelo V; Scarabino T; Liuzzi A
J Clin Endocrinol Metab; 1995 Aug; 80(8):2523-5. PubMed ID: 7629253
[TBL] [Abstract][Full Text] [Related]
14. Receptor imaging with 111In-pentreotide and 123I-methoxybenzamide, and inhibition tests with octreotide and bromocriptine of mixed growth hormone/prolactin-secreting pituitary tumors.
Panza N; Rambaldi PF; Battista C; Ambrosio G; Cascini GL; Schillirò F; Mansi L
Biomed Pharmacother; 1999 Aug; 53(7):319-22. PubMed ID: 10472432
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
17. (99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy.
Colao A; Ferone D; Lombardi G; Lastoria S
Clin Endocrinol (Oxf); 2002 Jun; 56(6):713-21. PubMed ID: 12072040
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
Scherfler C; Scholz SW; Donnemiller E; Decristoforo C; Oberladstätter M; Stefanova N; Diederen E; Virgolini I; Poewe W; Wenning GK
Neuroimage; 2005 Feb; 24(3):822-31. PubMed ID: 15652317
[TBL] [Abstract][Full Text] [Related]
19. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
[TBL] [Abstract][Full Text] [Related]
20. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy.
Ferone D; de Herder WW; Pivonello R; Kros JM; van Koetsveld PM; de Jong T; Minuto F; Colao A; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2008 Apr; 93(4):1412-7. PubMed ID: 18211974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
